Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Accounts Payables (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Accounts Payables for 12 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables rose 18.58% year-over-year to $4.2 million, compared with a TTM value of $4.2 million through Dec 2025, up 18.58%, and an annual FY2025 reading of $4.2 million, up 18.58% over the prior year.
  • Accounts Payables was $4.2 million for Q4 2025 at Abvc Biopharma, up from $4.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $4.3 million in Q2 2025 and bottomed at $2085.0 in Q2 2022.
  • Average Accounts Payables over 5 years is $2.6 million, with a median of $3.5 million recorded in 2023.
  • The sharpest move saw Accounts Payables plummeted 58.69% in 2022, then increased 18.58% in 2025.
  • Year by year, Accounts Payables stood at $16497.0 in 2021, then crashed by 87.36% to $2085.0 in 2022, then skyrocketed by 170084.75% to $3.5 million in 2023, then fell by 1.1% to $3.5 million in 2024, then rose by 18.58% to $4.2 million in 2025.
  • Business Quant data shows Accounts Payables for ABVC at $4.2 million in Q4 2025, $4.0 million in Q3 2025, and $4.3 million in Q2 2025.